“Mucosal Profiling of Pediatric-Onset Colitis and IBD Reveals Common Pathogenics and Therapeutic Pathways,” published in Cell, identifies defective cAMP signaling and platelet activation as key drivers in pediatric inflammatory bowel disease. The study highlights that the PDE inhibitor dipyridamole restored immune homeostasis and promoted mucosal healing in a pilot study of nine children. Read the full study at ScienceDirect.
Leave a Reply